Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-PI-2620 Tau PET in Progressive Supranuclear Palsy
2023-508718-40-00Phase 2Authorised
- Sponsor
- IDIBAPS
- Start
- Mar 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of 18F-PI-2620 in progressive supranuclear palsy (PSP) and Parkinson's disease (PD) (3 arms), sponsored by IDIBAPS. Primary endpoint: PI-2620 uptake determined by standard uptake value ratio (SUVR). Planned start Mar 2024; status: authorised.
02
Drugs
18F-PI-2620
03
Conditions
progressive supranuclear palsy (PSP)Parkinson's disease (PD)
Beyond the preview
Go deeper on 2023-508718-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508718-40-00.